Log in

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Sells $57,800.00 in Stock

Last updated on Thursday, July 2, 2020 | 2020 MarketBeat

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Brian Andrew Mitchell sold 4,000 shares of the company's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $14.45, for a total value of $57,800.00.

Brian Andrew Mitchell also recently made the following trade(s):

  • On Monday, June 1st, Brian Andrew Mitchell sold 4,000 shares of GenMark Diagnostics stock. The stock was sold at an average price of $9.72, for a total value of $38,880.00.
  • On Thursday, May 28th, Brian Andrew Mitchell sold 2,021 shares of GenMark Diagnostics stock. The shares were sold at an average price of $9.52, for a total transaction of $19,239.92.
  • On Tuesday, May 5th, Brian Andrew Mitchell sold 703 shares of GenMark Diagnostics stock. The stock was sold at an average price of $13.49, for a total transaction of $9,483.47.
  • On Friday, May 1st, Brian Andrew Mitchell sold 4,000 shares of GenMark Diagnostics stock. The shares were sold at an average price of $12.44, for a total transaction of $49,760.00.
  • On Monday, April 20th, Brian Andrew Mitchell sold 8,000 shares of GenMark Diagnostics stock. The stock was sold at an average price of $8.00, for a total transaction of $64,000.00.

Shares of NASDAQ GNMK traded up $0.21 during mid-day trading on Thursday, hitting $14.92. The company had a trading volume of 2,359,800 shares, compared to its average volume of 2,377,428. The company has a market capitalization of $923.40 million, a PE ratio of -20.72 and a beta of 3.04. The business's 50-day simple moving average is $11.20 and its 200 day simple moving average is $7.22. GenMark Diagnostics, Inc has a 1-year low of $3.36 and a 1-year high of $15.97. The company has a debt-to-equity ratio of 5.52, a current ratio of 3.15 and a quick ratio of 2.78.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings results on Monday, May 4th. The medical equipment provider reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.02. The company had revenue of $38.74 million for the quarter, compared to the consensus estimate of $38.70 million. GenMark Diagnostics had a negative return on equity of 310.58% and a negative net margin of 40.18%. On average, analysts expect that GenMark Diagnostics, Inc will post -0.42 EPS for the current year.

A number of large investors have recently modified their holdings of the stock. Bank of Montreal Can lifted its stake in GenMark Diagnostics by 29.5% in the fourth quarter. Bank of Montreal Can now owns 10,239 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 2,333 shares during the last quarter. Citigroup Inc. raised its holdings in shares of GenMark Diagnostics by 21.2% in the 1st quarter. Citigroup Inc. now owns 16,127 shares of the medical equipment provider's stock valued at $66,000 after purchasing an additional 2,819 shares in the last quarter. ETF Managers Group LLC lifted its position in shares of GenMark Diagnostics by 11.4% during the 1st quarter. ETF Managers Group LLC now owns 38,865 shares of the medical equipment provider's stock worth $158,000 after purchasing an additional 3,984 shares during the last quarter. Wrapmanager Inc. grew its stake in shares of GenMark Diagnostics by 6.2% during the fourth quarter. Wrapmanager Inc. now owns 68,163 shares of the medical equipment provider's stock worth $328,000 after purchasing an additional 3,992 shares in the last quarter. Finally, Stifel Financial Corp grew its stake in shares of GenMark Diagnostics by 19.6% during the fourth quarter. Stifel Financial Corp now owns 25,793 shares of the medical equipment provider's stock worth $126,000 after purchasing an additional 4,224 shares in the last quarter. 83.99% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently weighed in on the stock. Canaccord Genuity reiterated a "buy" rating and issued a $9.00 target price on shares of GenMark Diagnostics in a report on Wednesday, March 11th. Cowen lifted their price objective on GenMark Diagnostics from $10.00 to $15.00 and gave the company an "outperform" rating in a research note on Tuesday, May 5th. Zacks Investment Research downgraded GenMark Diagnostics from a "buy" rating to a "hold" rating in a report on Tuesday, April 28th. ValuEngine cut GenMark Diagnostics from a "buy" rating to a "hold" rating in a report on Thursday. Finally, Needham & Company LLC lifted their target price on GenMark Diagnostics from $11.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, May 5th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. GenMark Diagnostics presently has an average rating of "Hold" and an average target price of $11.10.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Recommended Story: What is quantitative easing?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

6 Stocks to Help You Profit Off the Coronavirus PPE Boom

Every major global event brings with it changes to our national lexicon. Before the Covid-19 pandemic, few Americans knew what the initials PPE stood for. Today, virtually anyone knows that PPE stands for personal protective equipment.

At the onset of the mitigation policies, the goal of flattening the curve was being done to prevent our health care system from becoming overwhelmed. Part of that concern stemmed from a shortage of personal protective equipment. These are the masks, gloves, goggles and gowns that help protect medical workers against viral or bacterial infections.

As the novel coronavirus became labeled a global pandemic, the global mantra became to “flatten the curve” in an effort to prevent our healthcare system from being overwhelmed.

The United States is being referred to as being on a war time footing. Manufacturers that were already producing PPE have significantly ramped up capacity. And many companies are converting their excess manufacturing capacity to produce personal protective equipment.

In fairness, this may only be a reason for some of these companies to “keep the lights on” right now. But many of these companies have a good story to tell. And it’s that story that can make them solid investments in the future.

View the "6 Stocks to Help You Profit Off the Coronavirus PPE Boom".

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.